MIAT and neoplasm: SNHG12 enhances tumor progression and sunitinib resistance in RCC by upregulating CDCA3 [36], while MIAT affects patient prognosis by promoting KIRC cell proliferation and metastasis through miR-29c-dependent Loxl2 regulation.Silencing MIAT was found to inhibit in vitro cell proliferation, migration, and invasion, as well as suppress tumor formation in vivo in KIRC according to animal experiments [37].